PLATFORM TECHNOLOGY

PLATFORM TECHNOLOGY

PIPELINES

Below is the current status of PLABiologics’ stem cell therapy pipelines, based on PLAB’s innovative technology.

Project Indication Status Discovery Preclinical GLP-Tox Pre-IND Clinical Trials (P1/P2/P3)
Project
UNIPla®-F
Indication
Polycystic Ovary Syndrome (PCOS)
Status
Pre-IND
  • Discovery
  • Preclinical
  • GLP-Tox
  • Pre-IND
  • Clinical Trials (P1/P2/P3)
Project
UNIPla®-E
Indication
Macular Degeneration
Status
GLP-Tox
  • Discovery
  • Preclinical
  • GLP-Tox
  • Pre-IND
  • Clinical Trials (P1/P2/P3)
Project
SUNIPla®-M
Indication
Metabolic Dysfunction-Associated Steatohepatitis
Status
Preclinical
  • Discovery
  • Preclinical
  • GLP-Tox
  • Pre-IND
  • Clinical Trials (P1/P2/P3)
Project
UNIPlax®
Indication
Tissue Repair
Status
Preclinical
  • Discovery
  • Preclinical
  • GLP-Tox
  • Pre-IND
  • Clinical Trials (P1/P2/P3)

UNIPla®

Technology for the isolation and cultivation
of highly purified placental chorionic plate-
derived mesenchymal stem cells.

  • The earliest stage of MSCs
  • High-purity isolation quickly and easily without mixing of other cells
  • Superior proliferative potentials as the earliest stage of MSCs
  • No ethical problem.
  • Multi-lineage differentiation potentials
  • Accessibility to obtain of abundant stem cells.
  • Immunosuppressive function

SUNIPla®

Technology for generating
functionally enhanced stem cells

  • High safety with non-chromosomal insertion
  • High efficiency of gene introduction.
  • Stable cell line
  • Easy and simple operation.
  • Clear mode of action (MoA).